

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

In accordance with letter dated
September 27, 2013,

1. Capital Region Medical Center
Nuclear Medicine Department
2. 1125 Madison
P.O. Box 1128
Jefferson City, MO 65102

3. License number 24-12699-01 is amended in its entirety to read as follows:

4. Expiration date June 30, 2015

5. Docket No. 030-02375

Reference No.

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

- A. Any byproduct material permitted by 10 CFR 35.100
- B. Any byproduct material permitted by 10 CFR 35.200
- C. Any byproduct material permitted by 10 CFR 35.300
- D. **Iodine-125, as permitted by 10 CFR 35.400**

- A. Any
- B. Any
- C. Any

- A. As needed
- B. As needed
- C. **One curie**

- D. **Sealed Sources (Theragenics Corporation I-Seed Model 125.S06; Bard Brachytherapy, Inc. Model STM 1251; 3M Health Physics Services Model 6711; BEBIG Model 125.S06; Best Medical International, Inc. (formerly Best Industries), Model 2301; Implant Sciences Corporation Model 3500; International Brachytherapy, Inc. Intersource Model 1251L; IsoAid, L.L.C. Model IAI-125A; Core Oncology, Inc. (formerly Mills Biopharmaceuticals), Models 125SL and 125SH; and North American Scientific, Inc., Model MED3631)**

- D. Two curies

- E. **Palladium-103, as permitted by 10 CFR 35.400**

- E. Sealed Sources (Theragenics Corporation **TheraSeed** Model 200; **Best Medical International, Inc. (formerly Best Industries), Model 2335; International Brachytherapy, Inc. Intersource Model 1032P; and North American Scientific, Inc., Model MED3633)**

- E. Two curies

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-12699-01Docket or Reference Number
030-02375**Amendment No. 70**

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. **through E.** Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 1125 Madison, Jefferson City, Missouri.
- 11. The Radiation Safety Officer (**RSO**) for this license is Kenneth L. Andrews, M.S., DABR.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use


S. J. Westgate, M.D.	10 CFR 35.400.
Conrad Balcer, D.O.	10 CFR 35.100 and 35.200.
Mark Phillip Bryer, M.D.	10 CFR 35.300 and 35.400.
William L. Schlegel, D.O.	10 CFR 35.100 and 35.200.
Rodney Adkison, D.O.	10 CFR 35.100, 35.200, and 35.300.
Joseph M. Bean, M.D.	10 CFR 35.300 and 35.400.
James Russell Allen, M.D.	10 CFR 35.300 and 35.400.
Patrick J. Morello, M.D.	10 CFR 35.100 and 35.200.
Matthew Hrastich, D.O.	10 CFR 35.100 and 35.200.
Mitchell T. Godbee, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Dennis Luetkemeyer, M.D.	10 CFR 35.100 and 35.200.
Jeffrey S. Sanders, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
24-12699-01Docket or Reference Number
030-02375**Amendment No. 70****Authorized Users****Adam C. Patterson, M.D.****Material and Use****10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).**

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated December 6, 2004; and
- B. Facsimile letters dated May 26, 2005, June 6, 2005, June 7, 2005, March 8, 2006, and February 17, 2010.


FOR THE U.S. NUCLEAR REGULATORY COMMISSIONDate JAN 02 2014

By

Sara A.B. Forster, M.S.
Materials Licensing Branch
Region III